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Background: The NKG2D receptor confers important activating signals to NK cells via ligands expressed during
cellular stress and viral infection. This receptor has generated great interest because not only is it expressed on NK
cells, but it is also seen in virtually all CD8+ cytotoxic T cells and is classically considered absent in CD4+ T cells.
However, recent studies have identified a distinctive population of CD4+ T cells that do express NKG2D, which
could represent a particular cytotoxic effector population involved in viral infections and chronic diseases. On the
other hand, increased incidence of human papillomavirus-associated lesions in CD4+ T cell-immunocompromised
individuals suggests that CD4+ T cells play a key role in controlling the viral infection. Therefore, this study was
focused on identifying the frequency of NKG2D-expressing CD4+ T cells in patients with cervical intraepithelial
neoplasia (CIN) 1. Additionally, factors influencing CD4+NKG2D+ T cell expansion were also measured.
Results: Close to 50% of patients with CIN 1 contained at least one of the 37 HPV types detected by our
genotyping system. A tendency for increased CD4+ T cells and CD8+ T cells and decreased NK cells was found in
CIN 1 patients. The percentage of circulating CD4+ T cells co-expressing the NKG2D receptor significantly increased
in women with CIN 1 versus control group. Interestingly, the increase of CD4+NKG2D+ T cells was seen in patients
with CIN 1, despite the overall levels of CD4+ T cells did not significantly increase. We also found a significant
increase of soluble MICB in CIN 1 patients; however, no correlation with the presence of CD4+NKG2D+ T cells was
seen. While TGF-beta was significantly decreased in the group of CIN 1 patients, both TNF-alpha and IL-15 showed
a tendency to increase in this group.
Conclusions: Taken together, our results suggest that the significant increase within the CD4+NKG2D+ T cell
population in CIN 1 patients might be the result of a chronic exposure to viral and/or pro-inflammatory factors, and
concomitantly might also influence the clearance of CIN 1-type lesion.
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Cervical cancer is one of the most common malignant tu-
mors among women in developing countries [1,2]. Clinical,
molecular and epidemiological data have established a
strong link between human papillomavirus (HPV) and cer-
vical squamous cell carcinoma development [3-7]. However,
before cancer is established, the cervix must go through a
series of steps ranging from cervical intraepithelial neoplasia
(CIN) grade 1, 2 and 3, before eventually progressing to in-
vasive carcinoma [8-10]. CIN 1, the most benign cervical
intraepithelial lesion, will spontaneously regress within 12 to
24 months post-diagnosis of the dysplastic smear in most
cases, and this is especially true in those women with non-
oncogenic HPV infections [11-15]. It is well accepted that
the immune response mediated by CD4+ T cells plays an
important role in the regression or progression of CIN to-
wards later stages. To make evident the critical involvement
of the CD4+ T cell response, there is the fact that women
infected with human immunodeficiency virus have an in-
creased incidence of squamous intraepithelial lesions, mostly
because an increased risk of HPV infection, as well as due
to the immunosuppressive state [16-19]. Thus, HPV-specific
responses have suggested that CD4+ T cells are invaluable
effectors used to control of HPV infection, disease regres-
sion and clearance [20-22]. Consequently, a number of
therapeutic approaches designed to target HPV E6/E7 anti-
gens and the induction of a robust Th1-mediated immune
response have been developed for patients diagnosed with
either CIN or established cervical cancer [23-26]. Consistent
with a protective IFN-γ-producing Th1 phenotype, a shift
towards a Th2-type immune response has been associated
with cervical cancer progression [27]. Thus, it is clear that
Th1-derived cytokines might stimulate an effective cytotox-
icity response mediated mainly by CD8+ T cells. However,
the existence of a unique subset of CD4+ T cells endowed
with cytolytic capacities has, several decades ago, also been
described [28-30], but it has not been until recently that
their physiological role has begun to be clarified. Why do
some CD4+ Tcells exhibit cytotoxic behavior? This has been
an important question resolved, in part, by the fact that
these cells express the activating receptor NKG2D.
NKG2D is a C-type lectin-like immunoreceptor
encoded within the NK gene complex on human chromo-
some 12 [31] with wide expression on NK cells, CD8+ T
cells and γδ T cells [32,33]. NKG2D is evolutionary
conserved in primates and rodents and its symmetric
structure consists of a homodimer assembled with
transmembrane adaptor molecules, such as DAP10 (in
human and mouse) and DAP12 (only in mouse)
[34,35]. Upon engagement by natural ligands, such as
MHC class I-related chain molecules A and B (MICA
and MICB), the complex NKG2D/DAP10 will signal
through recruitment of phosphatidyl inositol-3 kinase
(PI3K), which will ultimately activate signaling pathwaysinvolved in cell survival and release of cytotoxic granules
promoting a potent role in tumor destruction or killing of
virus-infected cells [36-39]. The cytotoxic signature of
NKG2D explains why this receptor had traditionally been
confined to NK cells and CD8+ cytotoxic T lymphocytes;
however, several studies over the last ten years have
identified a rare population of CD4+ T cells that do ex-
press NKG2D, which could represent a particular cyto-
toxic population involved in viral infections and chronic
diseases. For instance, Groh et al. reported a substan-
tial number of peripheral and synovial CD4+CD28- T cells
with expression of NKG2D in patients with rheumatoid
arthritis; these CD4+NKG2D+ T cells apparently influenced
by pro-inflammatory cytokines such as IL-15 or TNF-α
promoted a cytotoxic response against synoviocytes with
anomalous expression of MIC molecules [40]. Therefore,
the costimulatory signal triggered by the engagement
NKG2D/NKG2D ligands coupled with suboptimal stimula-
tion via TCR will induce important cytokine and cytotoxic
responses, thereby self-perpetuating the CD4+NKG2D+
T cell autoreactivity in rheumatoid arthritis [40,41].
However, the molecular basis influencing the expres-
sion of cytotoxicity-related receptors on CD4+ T cells
remain still under evaluation; however, it is though
that chronic antigenic stimulation, such as occurring
with some viral infections might lead to NKG2D ex-
pression. At least, the existence of a large proportion
of CD4+NKG2D+ T cells has been reported in HTLV-1-
associated neurologic disease, as well as in human
cytomegalovirus-seropositive individuals [42,43]. Para-
doxically, persistent expression of MIC in inflamed tis-
sues in patients with juvenile-onset systemic lupus
erythematosus could also promote the expansion of a
TGF-β and IL-10-producing CD4+NKG2D+ T cell
population, which would ameliorate the activity of disease
[44]. All the above data, apparently contradictory, resulted
in the proposal of two distinct populations, one with in-
flammatory cytokine profile and cytotoxic signature, the
other one, a normally-occurring CD4+NKG2D+ T cell
population with immunoregulatory activities [44], although
this suppressor population could be exploited by tumors as
an strategy to avoid the immune attack. Certainly, substan-
tial number of MIC-dependent CD4+NKG2D+ T cells has
been found in patients with different malignancies, and
such population has shown to exert suppressor activities
through anti-inflammatory cytokines and Fas ligand-
mediated suppression [45]. Thus, it is expected that
NKG2D will play a dual role on the particular CD4+ T cell
population and the decision to adopt a role or the other,
will depend in part of the extracellular milieu conditions
in which this population is present.
In the particular case of CIN 1, majority of the lesions
will spontaneously regress as previously mentioned;
however, some of them in which HPV establishes as a
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gress to advanced stages increasing the risk of cervical
cancer development. In this scenario, it is firstly import-
ant to describe whether the CD4+NKG2D+ T cell popu-
lation is also expanded in patients with early cervical
neoplasia, and secondly, to explore whether inductor
factors of this population are present in the same group
of patients. For that reason, here we addressed both
goals and we demonstrated that CIN 1 patients show an
increase of CD4+NKG2D+ T cells even when overall
levels of CD4+ T cells did not increase. We also found a
significant increase of soluble MICB in CIN 1 patients;
however, no correlation with the presence of CD4+
NKG2D+ T cells was seen. While TGF-β was signifi-
cantly decreased in the group of CIN 1 patients, both
TNF-α and IL-15 showed a tendency to increase (al-
though not significantly) in this group. Therefore, these
findings suggest that the expansion of CD4+NKG2D+
T cells in CIN 1 patients might be under the control of
other pro-inflammatory factors still unknown at the
moment.
Methods
Patients and normal donors
In total, we recruited 33 patients that were first subjected
to conventional colposcopic evaluation and finally diag-
nosed with cervical intraepithelial neoplasia (CIN) grade 1
based on histological analyses. All patients were attended
at Gynecology Departments, belonging to Hospital
Civil de Guadalajara (OPD) and Centro Médico
Nacional de Occidente, IMSS (Guadalajara, México).
Thirty age/gender matched healthy volunteers without
a history of human papillomavirus (HPV) infection or
uterine cervix lesions were also included as control
group. Signed informed consent and patient data, includ-
ing age, and smoking, drug or alcohol use history was
given prior to sample collection. The age range of the CIN
1 patients was 20–61 years (mean ± SEM was 34 ±
1.6 years) and that of the control group was 24–61 years
(mean ± SEM was 36.5 ± 1.9 years).
Inclusion and exclusion criteria
Patients were included if they were colposcopically and
histopathologically diagnosed as CIN 1. Patients were
not included in the study if they had other documented
incidences of current inflammatory processes (such as
autoimmune or allergic disorders). Control women were
negative for HPV infection; they were excluded if they
were positive for any HPV genotype.
Ethical considerations
The study was approved by the local ethical Committee
of the Centro Universitario de Ciencias de la Salud,
Universidad de Guadalajara (Guadalajara, Mexico), inaccordance with the guidelines of the Mexican Official
Standard (Norma Oficial Mexicana NOM) and the World
Medical Association Declaration of Helsinki (adopted by
the 59th WMA General Assembly, Seoul, South Korea,
2008). All women were informed of their rights, the goals
of the study and the importance of their participation. The
procedures used for collection of samples were identical
to those routinely used in the clinical setting and those
used for patients not being part of this study.
Sample collection
Five mL of peripheral blood (PB) was collected into
heparin-coated tubes and used for flow cytometry assays.
PB was also obtained without heparin in order to separ-
ate serum, which was stored at −70°C until analysis by
ELISA. Cervical scrape specimens were gently collected
from the squamocolumnar junction of the cervix using a
sampling brush and were stored at 4°C prior to HPV
genotyping.
HPV genotyping
LINEAR ARRAY® HPV Genotyping Test was performed
in accordance with the manufacturer’s recommendations
(Roche Diagnostics). Briefly, DNA was extracted from
cervical scrapes and amplified in a total volume of
100 μL containing 50 μL of DNA and 50 μL of the mas-
ter mixture provided by the manufacturer. PCR was
performed on a thermocycler T3 (Biometra, Göttingen,
Germany) and PCR products were stored at −30°C until
use. Colored signals on the strips were read by the naked
eye and interpreted according to the LINEAR ARRAY refer-
ence guide. Each hybridization strip included two β-globin
probe lines (β-globin high and β-globin low), as a positive
control for the integrity of the DNA sample.
Expression of the immunoreceptor NKG2D on CD4+ T cell
population
CD3 FITC (Santa Cruz Biotech, clone UCH-T1), CD4
PECy5 (Biolegend, clone RPA-T4), CD8 PECy5 (Biolegend,
clone RPA-T8), CD56 PECy5 (Biolegend, clone HCD56)
and NKG2D PE (Biolegend, clone 1D11) were used to
identify the expression of NKG2D on CD4+ T cells, CD8+
T cells and NK cells in a three-color protocol for flow cy-
tometry. Cells were stained for 45 min at 4°C protected
from the light. After incubation, but before washing, eryth-
rocytes in the blood were lysed using BD FACS Lysis Buffer
(BD Biosciences). Each tube with 100 μL of blood was di-
luted with 2 mL of 1× lysis buffer. Tubes were vortexed for
ten seconds and then incubated for 15 min protected from
the light at room temperature. Cells were then vortexed
rapidly and centrifuged at 300 g for 6 min. The lysed eryth-
rocytes and lysis solution were decanted and the pellet was
washed with 2 mL of PBS/0.1% sodium azide. Cells were
centrifuged again, and resuspended in 500 μL of PBS/0.5%
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other mononuclear cells using morphological parameters,
namely different coordinates on the forward and side scat-
ter axis, during the flow cytometry scan. Gate was drawn
around the lymphocyte population, which was then ana-
lyzed separately using the triple marking antibody scheme.
A FACSAria flow cytometer (BD Biosciences) was used to
acquire ten thousand events in the lymphocyte region for
each condition. It is important to mention that this proto-
col was also extended to calculate the percentages of CD4+
T cells, CD8+ T cells and NK cells in our two study groups.
ELISA assays to quantify MICA, MICB, TGF-β, TNF-α, and
IL-15
Commercial pre-coated ELISA plates were used to quan-
tify serum MICA, MICB (both from RayBiotech, Inc.
Norcross, GA), TGF-β (R&D Systems, Minneapolis,
MN), TNF-α, and IL-15 (both from BioLegend, San
Diego, CA). Immediately prior to use, sera were thawed
from −70°C storage. All samples were run by duplicate
and values reported as average of the duplicates. The
manufacturer’s instructions were followed for the assays.
Briefly, plates were washed and samples and standards
were pipetted into the wells. Plates were sealed and in-
cubated overnight at 4°C. Biotinylated detection anti-
bodies were added and incubated for 1 hour at room
temperature on an orbital shaker. Avidin-HRP detection
complexes were added and incubated. Next, the plates
were incubated with the chromogenic substrate solution
and covered from the light. Stop solution was trans-
ferred to each well and samples were read within
30 minutes. Absorbance was calculated as absorbance
at 450 nm minus absorbance at 570 nm. The values of
blanks were subtracted from sample values and curve
fitting was calculated using a 4-parameter logistic
curve-fitting algorithm (CurveExpert Basic, v 1.4).
Statistical analysis
Results of soluble MICA, MICB, TGF-β, TNF-α, and
IL-15, as well as percentages of NKG2D expression on
T cells and NK cells were expressed as mean ± SEM.
Data were tested for normal distribution using Shapiro-
Wilk test for small sample size. Due to the non-normal
distribution, data were analyzed with Mann–Whitney U
test. All the statistical analyses were performed consider-
ing p < 0.05 to be significant using SPSS 15.0 software
(SPSS, Chicago, IL, USA).
Results
Distribution of human papillomavirus (HPV) genotypes
Some studies have reported a HPV prevalence ranged
from 67.1% to 68.3% for Europe, South/Central America
[46]. Using a commercial kit for detection of 37 high-
and low-risk HPV genotypes we found that close to 50%of the patients with cervical intraepithelial neoplasia
(CIN) 1 contained at least one of the 37 HPV genotypes.
With regard to the HPV genotypes of infected patients,
we found a wide dispersion of different strains of HPV.
Infection with high-risk HPV was present in 75% of CIN
1 patients that were positive for at least one viral strain
(Table 1). Although the most common strains of high-
risk and low-risk HPV are 16, 18 and 6, 11, respectively
[46,47], in our viral typing the most common strain of
high-risk HPV was 51, and the most common low-risk
strain was 84 (Table 1). Interestingly, 37.5% of CIN 1 pa-
tients infected with HPV presented more than one strain
of HPV (co-infection cases). In these cases, it is interest-
ing to note that 100% of the patients were co-infected
with at least one low-risk viral sub-type.
Changes in numbers of lymphocyte populations
An effective T cell response might be important for CIN
1 regression. Although, the frequency of the different
lymphocyte populations in women with CIN 1 has been
well documented in the literature, in this study we
wanted to re-evaluate the frequencies of CD4+ T cells,
CD8+ T cells, and NK cells, in order to rule out whether
a possible increase in the pool of NKG2D-expressing
CD4+ T cells might be due to variations in the frequency
of these populations. Patients with CIN 1 lesions (n = 33)
and controls (n = 30) were examined. Lymphocyte counts
(expressed as percentages) were performed using the
cytograms, according to the characteristics of forward
scatter (FS) and side scatter (SS). Thus, in CIN 1 patients,
we found a mean of 27.07 ± 1.22% (range 15.8 ± 45.4%),
whereas in healthy controls a mean of 28.61 ± 1.35%
(range 23.2 ± 34.2%) was found. We observed a tendency
for increased CD4+ T cells and CD8+ T cells and de-
creased NK cells in CIN 1 patients. CD4+ T cells were
present at 38% of the lymphocyte gate of peripheral
blood mononuclear cells (PBMCs) in healthy controls
and 40% in CIN 1 patients. CD8+ T cells increased
from 16% to 20% in patients versus controls. CD56+
(NK) cells decreased from 13% to 11%. Only the in-
crease in CD8+ T cells was significant (p = 0.015) as
can be seen in Figure 1.
Increased CD4+NKG2D+ T cells and soluble MICB in CIN 1
patients
CD4+ T cells that express NKG2D may have either
cytotoxic or immunoregulatory roles. In this study,
CD4+NKG2D+ T cells were found to be significantly
increased in CIN 1 patients versus controls (Figure 2a).
Cells from the lymphocyte gate were gated according
to CD3 and CD4 co-expression and NKG2D was mea-
sured on the double positive CD3+CD4+ cells in controls
(Figure 2b) and patients (Figure 2c). CD4+NKG2D+ T cells
in CIN 1 patients were significantly increased versus controls
Table 1 HPV genotypes in patients with histologically
confirmed diagnosis of CIN 1
Patient with diagnosis
of CIN-1
Age Infection HPV infection
(Viral subtyping)
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solute NKG2D levels were found to decrease in CD8+ T
cells and NK cells from CIN 1 samples (data not shown). In
accordance with the fact that binding of soluble MIC mole-
cules can lead to NKG2D down-regulation, soluble MICB
was found to be significantly increased in CIN 1 patients(1.8 ng/mL versus 0.04 ng/mL; p= 0.03) as shown in
Figure 3b. While soluble MICA levels visually increased, this
result was not significant (413 pg/mL versus 119 pg/mL;
p = 0.18) as shown in Figure 3a.
Soluble levels of TGF-β, TNF-α, and IL-15
With CD4+NKG2D+ T cell population being increased
in CIN 1 patients, it would appear that a less quiescent
cellular milieu was present, as it is known that exposure
to pro-inflammatory cytokines can induce the expression
of NKG2D on CD4+ T cells [40]. In accordance with
this, anti-inflammatory TGF-β was found to decrease
from 35 pg/mL (in controls) to 26 pg/mL in CIN 1 pa-
tients; p = 0.014 (Figure 4a). In turn, non-significant in-
creases in pro-inflammatory TNF-α (from 0.2 pg/mL to
1.8 pg/mL; p = 0.31) and IL-15 (undetectable in controls)
were found (Figure 4b and 4c, respectively). Interest-
ingly, the variation within the control group was very
low for TNF-α and IL-15, while CIN 1 patients displayed
extreme deviation. The majority of CIN 1 patients had
TNF-α and IL-15 levels similar to those of the controls;
however, a minority of patients presented levels sharply
higher. This might reflect a more chronic local inflam-
matory state that presupposes a minority of CIN 1 pa-
tients towards the development of chronic infections
and eventually to cervical cancer. It is notable that 3/6
patients who displayed the highest IL-15 levels, also
ranked as the highest producers of TNF-α.
Discussion
The infection with genital human papillomavirus (HPV)
is very common in sexually active women; however most
HPV infections are temporary, clearing within 12 to
24 months after diagnosis of the dysplastic smear or, in
fact, in a shorter period of time in those women with
non-oncogenic HPV infections [11,14,15]. Clinical mani-
festations of low-risk HPV infections (i.e. HPV6 and
HPV11) are commonly genital warts [48]; infections
with high-risk HPV types (i.e. HPV16 and HPV18) are
associated with the occurrence of cervical intraepithelial
neoplasia (CIN). CIN 1, the grade of the lesion in the
women in this study, is the most benign lesion and rarely
develops into cervical cancer [49,50]. While the main sub-
ject of this study was focused on CD4+NKG2D+ T cells
and potential factors associated with their expansion in
patients with CIN 1, our first step was to confirm HPV in-
fection and to identify the HPV genotypes present in our
group of patients. We found that close to 50% of the pa-
tients were positive for at least one of the 37 HPV types
detected by our genotyping system. Initially, this result
was cause for concern and led us to question the relatively
low percentage of HPV infection, as, based on
gynecological examination, a higher number of HPV-


















































Figure 1 CD8+ T cells are significantly increased in CIN 1 patients. Flow cytometric analysis of peripheral blood in CIN 1 patients or normal
donors was performed in order to evaluate variations in the percentages of T cells and NK cells. Gate was drawn around the lymphocyte
population, which was then analyzed separately with the corresponding antibodies (CD3+ FITC/CD4+ PECy5, CD3+ FITC/CD8+ PECy5, and CD3-
FITC/CD56+ PECy5 for detection of CD4 T cells, CD8 T cells and NK cells, respectively). Analysis from the lymphocyte gate shows that both CD4+
T cells and CD8+ T cells were increased in CIN 1 patients, while NK cells were diminished; however, we only observed a significant increase in the
CD8+ T cell population. Statistical analysis was performed through Mann–Whitney U test and data were expressed as mean ± SEM; *p = 0.015.
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likely explanation is the possibility that a higher number
of patients with CIN 1 than recorded by the DNA-based
test were actually positive for any of the HPV genotypes.
This is based mainly on the fact that some of the patients
reported as negative via the DNA-based test for viral in-
fection presented persistent lesions up to 12 months after
initial examination (data not shown). Another reason to
support the diagnosis of a HPV infection (in the absence
of a positive test score) was based on colposcopic features
suggestive of HPV infection. Therefore, a conceivable
explanation for the low frequency of HPV might be
largely attributed to the accuracy of our viral typing
method (i.e. unable to detect all samples with low viral
load) or another possibility might be the infection with
other strains of HPV, different than those detected by
our system.
An interesting result has been the finding that low risk
viral types are increased in CIN 1 patients with multiple
viral infections. If we look at our patients infected with
only one viral strain (Table 1), we see that high-risk
strains predominate at 4:1 ratio (80% of the CIN 1 pa-
tients infected with a single strain are positive for high-
risk strains). This is in line with previous research that
has shown that in women negative for HPV, the cu-
mulative probability of acquiring an oncogenic HPV
strain during a 12-month follow-up period was 0.32,
compared with 0.18 for non-oncogenic strains [51].
This argues that either high-risk strains have a higher
prevalence in the general population, or that high-
risk strains have a greater “staying power” in patients.
However, whatever the case, the vast majority of
HPV-infected women mount an effective immuneresponse to assist the infection clearance without
medical intervention [12].
It is well known that CD4+ T cell-regulated cellular
immune response plays a central role in the control and
resolution of HPV-associated cervical lesions [20-22].
For instance, CD4+ T cells polarized into a Th1 pheno-
type secrete consistent amounts of IFN-γ, creating a mi-
lieu in which CD8+ T cells are activated to generate an
effective cytotoxic response against infected cells. This
concept is supported by the fact that a shift from Th1-
towards a Th2-type immune response is associated with
cervical cancer progression [27]. Although HPV life
cycle does not seem to cause apparent systemic viraemia
and the control of the viral infection is practically con-
fined to the local immune response, several studies have
shown a co-dependency between local T cell-mediated
responses and those mediated by peripheral blood T
cells [52]. The role of systemic immunity is exemplified
in women spontaneously resolving CIN 1; in these pa-
tients it has been shown that T cells proliferating in re-
sponse to HPV16 E2 secrete high levels of IFN-γ, which
is consistent with a Th1 response [53]. In the present
study, we did not perform assays to test the functionality
of the peripheral T cell pool; our goal was merely to re-
evaluate the frequencies of CD4+ T cells, CD8+ T cells,
and NK cells in order to rule out whether a possible in-
crease in the pool of NKG2D-expressing CD4+ T cells
might be due to variations in the frequency of the
above-mentioned populations. However, the fact that the
potent regulatory cytokine TGF-β was significantly de-
creased in CIN 1 patients versus the control group might
suggest the predominance of a less quiescent cellular mi-



































































Figure 2 NKG2D-expressing CD4+ T cells significantly increase in patients with CIN 1. Three-color flow cytometric analysis to detect the
expression of NKG2D on peripheral CD4 T cells was carried out in CIN 1 patients and control donors. Cells from the lymphocyte gate were
subgated based on CD3 expression and CD4 co-expression. Then, changes in NKG2D expression on CD4+ T cell populations were evaluated. The
given percentages reflect the portion of cells positive for NKG2D within the given sub-population. There was a significant increase in CD4+NKG2D+
T cells in the group of CIN 1 patients when compared with normal donors (a). Representative experiment is showed in (b), CD3+CD4+ cells were
divided into two populations: NKG2D- and NKG2D+ (gate P7 and P8, respectively). It can be clearly seen a control donor practically negative
for CD4+NKG2D+ T cells. The other example in (c) shows a CIN 1 patient with a high percentage of CD4+NKG2D+ T cells. Statistical analysis
was performed through Mann–Whitney U test and data are expressed as median, which are represented as horizontal lines and 10th and
90th percentiles as whiskers. Extreme values are also showed (•); *p < 0.001.
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An example of the immunoregulatory role of TGF-β
during the development of CD8+ T cell responses is
clearly depicted in a murine model with intracellular
bacterial infection. In this study, Sanjabi et al. show that
the number of effector CD8+ T cells following Listeria
infection is under strict control of TGF-β and IL-15,
which exerted contrasting effects during clonal expan-
sion and contraction phases. While TGF-β supported
apoptosis of effector CD8+ T cells, IL-15 maintainedsurvival of CD8+ T cells during the contraction phase
[54]. As mentioned above, in our present study we ob-
served on one hand, that the level of TGF-β was signifi-
cantly reduced in CIN 1 patients (consistent with the
significant increase of systemic CD8+ T cells); while on
the other hand, we also found an increase of IL-15 in
this group, although this result was not significant.
However, our measurement system was limited to sol-
uble IL-15 in serum; thus, we cannot strictly exclude the



























































Figure 3 The highest levels of soluble MICA and MICB are seen in CIN 1 patients. Levels of soluble MICA and MICB were detected using
commercial ELISA kits. The highest levels for both MICA (a) and MICB (b) were found in CIN 1 patients when compared to healthy controls. While
the group of CIN 1 patients showed only a non-significant trend to high soluble MICA, the levels of soluble MICB were significantly augmented
in this group versus controls. Statistical analysis was performed through one-tailed Mann–Whitney U test and data are expressed as mean ± SEM
(horizontal lines). Absorbance values are shown as pg/mL (MICA) and ng/mL (MICB); *p = 0.03.
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CD8+ T cells through a complex mechanism termed
trans-presentation, which tightly regulates IL-15 responses
in NK cells and CD8+ T cells [55-57]. Likewise, it will be
important to understand further the role of IL-15 in the
progression of CIN advancing to cervical cancer, as this
cytokine has also, paradoxically, been implicated in cer-






























































Figure 4 Trend to decrease TGF-β and increase pro-inflammatory cyt
IL-15 in CIN 1 patients and control donors were quantified using commerc
in CIN 1 patients versus control group, TNF-α (b) and IL-15 (c) showed a tre
Statistical analysis was performed through Mann–Whitney U test and data
shown as pg/mL (TNF-α and IL-15) and ng/mL (TGF-β); *p = 0.014.expression of the inhibitory receptor CD94/NKG2A on
tumor-infiltrating CD8+ T lymphocytes [58].
Despite the fact that the role of IL-15 is well established
on cytotoxic lymphocytes (namely CD8+ T cells and NK
cells), there is also evidence that an atypical subset of CD4+
T cells endowed with apparent cytotoxic capabilities strictly
depend on IL-15 for their expansion. This has been docu-


































okines is seen in CIN 1 patients. Serum profiles of TGF- β, TNF-α, and
ial ELISA kits. While serum levels of TGF-β (a) were significantly lower
nd to be increased, although we did not find statistical differences.
are expressed as mean ± SEM (horizontal lines). Absorbance values are
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trans-presented by monocytes/macrophages contributes to
the survival and proliferation of NKG2D-expressing CD4+
T cells, which are the main mediators of the resulting endo-
thelial cell damage [59]. The innate NK-activating receptor
had traditionally been restricted to NK cells, CD8+ T cells,
and γδ+ T cells [32,33]; however, in recent years there has
been a wealth of evidence that strongly supports the exist-
ence of this receptor on CD4+ T cells, conferring an im-
portant innate-like cytotoxic signature to this particular
population. CD4+NKG2D+ T cells have been seen in
chronic viral infections [42,43], as well as in autoimmune
disorders, in which these cells may intensify the clinical man-
ifestations after TCR and NKG2D engagement [40,41,60,61].
Contradictory evidence has also tagged this particular popu-
lation with an immunosuppressive role in patients with can-
cer [46]. Thus, these apparently confounding data have led
to the proposal that two different CD4+NKG2D+ T cell sub-
sets might be operating in different clinical settings [45]. In
our present work, the substantial increase of CD4+NKG2D+
T cells (particularly observed in CIN 1 patients) is note-
worthy. The biological significance of these cells in our CIN
1 patients is unknown at the moment, as we do not yet have
any functional evidence to tag this cell population with either
pro-inflammatory or regulatory properties. However, it is im-
portant to remark that a high percentage of the patients in-
cluded in our study (almost 80%) were followed up for at
least 12 months and almost all the patients cleared their le-
sions without progressing to more advanced stages (data not
shown). Moreover, the few patients that had shown long-
term persistence of their lesions were clinically confirmed, at
the end of the follow-up period, to be free from dis-
ease. Particularly notable is the fact that one of these
patients, who also had a bacterial infection during the
4th follow-up ambulatory visit, showed the highest
percentage of CD4+NKG2D+ T cells (12.6%). Despite
the fact that we only measured this particular T cell
population at the beginning of our study, it is feasible
to speculate that persistent HPV lesions might create a
privileged setting in which the expression of NKG2D
on CD4+ T cells would be favored by an imbalance be-
tween anti- and pro-inflammatory stimuli. Interest-
ingly, Lee et al. have provided evidence showing that
TGF-β1 in plasma taken from patients with lung can-
cer or colorectal cancer impairs NK cell activity via
NKG2D down-regulation [62]. Thus, the significant
decrease of TGF-β might facilitate, in part, the increase
of CD4+NKG2D+ T cells observed in our CIN 1 pa-
tients. Additionally, it has also been demonstrated that
soluble MHC class I-related chain molecule A (MICA) is
associated with NKG2D down-regulation on NK cells and
CD8+ T cells is several malignant tumors [63-65]. The bio-
logical impact that soluble MICA and MICB might exert
on the particular subset of CD4+NKG2D+ T cells is notwell understood, but it has been proposed that pro-
inflammatory cytokines may neutralize the NKG2D
down-regulation induced by soluble MIC molecules in pa-
tients with autoimmune disease [40]. Thus, it is note-
worthy that our CIN 1 patients had notably higher
amounts of soluble MICA and MICB than the range seen
in the control group (although only MICB yielded a sig-
nificant difference); however, we did not observe any
resulting NKG2D down-regulation on CD4+ T cells,
supporting the idea that the observed pro-inflammatory
milieu might be contributing to the maintenance of CD4+
NKG2D+ Tcells during the regression of CIN 1.
Finally, the question remains as to why, in only some
cases, HPV persists as a chronic infection and may ad-
vance from CIN 1 to CIN 2/3 and eventually to cervical
cancer. Given our results, it is clear that more work is
still needed to elucidate whether pro-inflammatory or
regulatory activities are the main feature of CD4+
NKG2D+ T cells in the natural history of cervical
intraepithelial neoplasia grade 1.
Conclusions
Taken together, our results suggest that the significant
increase within the CD4+NKG2D+ T cell population in
CIN 1 patients might be the result of a chronic exposure
to viral and/or pro-inflammatory factors, and concomi-
tantly might also influence the clearance of CIN 1-type
lesion.
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